{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T11:50:05Z","timestamp":1791201005331,"version":"4.2.0"},"reference-count":53,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":477,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01AI091130"],"award-info":[{"award-number":["R01AI091130"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01CA155143"],"award-info":[{"award-number":["R01CA155143"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R21 CA143785"],"award-info":[{"award-number":["R21 CA143785"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P50CA136411"],"award-info":[{"award-number":["P50CA136411"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30CA16672"],"award-info":[{"award-number":["P30CA16672"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000888","name":"W.M. Keck Foundation","doi-asserted-by":"publisher","award":["01, pp-4"],"award-info":[{"award-number":["01, pp-4"]}],"id":[{"id":"10.13039\/100000888","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000862","name":"Doris Duke Charitable Foundation","doi-asserted-by":"publisher","award":["2008040"],"award-info":[{"award-number":["2008040"]}],"id":[{"id":"10.13039\/100000862","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005189","name":"Leukemia and Lymphoma Society","doi-asserted-by":"crossref","award":["6255-11"],"award-info":[{"award-number":["6255-11"]}],"id":[{"id":"10.13039\/100005189","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100005189","name":"Leukemia and Lymphoma Society","doi-asserted-by":"crossref","award":["7262-08"],"award-info":[{"award-number":["7262-08"]}],"id":[{"id":"10.13039\/100005189","id-type":"DOI","asserted-by":"crossref"}]},{"name":"The University of Texas MD Anderson Cancer IRG Program"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int. J. Cancer"],"published-print":{"date-parts":[[2014,12,15]]},"DOI":"10.1002\/ijc.28937","type":"journal-article","created":{"date-parts":[[2014,4,26]],"date-time":"2014-04-26T15:58:36Z","timestamp":1398527916000},"page":"2834-2846","source":"Crossref","is-referenced-by-count":33,"title":["Selective targeting of Toll-like receptors and OX40 inhibit regulatory T-cell function in follicular lymphoma"],"prefix":"10.1002","volume":"135","author":[{"given":"Kui Shin","family":"Voo","sequence":"first","affiliation":[{"name":"Department of Immunology; The University of Texas M.D. Anderson Cancer Center; Houston TX"},{"name":"Center for Cancer Immunology Research; The University of Texas M.D. Anderson Cancer Center; Houston TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myriam","family":"Foglietta","sequence":"additional","affiliation":[{"name":"Center for Cancer Immunology Research; The University of Texas M.D. Anderson Cancer Center; Houston TX"},{"name":"Department of Lymphoma and Myeloma; Division of Cancer Medicine; The University of Texas M.D. Anderson Cancer Center; Houston TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Percivalle","sequence":"additional","affiliation":[{"name":"Center for Cancer Immunology Research; The University of Texas M.D. Anderson Cancer Center; Houston TX"},{"name":"Department of Lymphoma and Myeloma; Division of Cancer Medicine; The University of Texas M.D. Anderson Cancer Center; Houston TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fuliang","family":"Chu","sequence":"additional","affiliation":[{"name":"Center for Cancer Immunology Research; The University of Texas M.D. Anderson Cancer Center; Houston TX"},{"name":"Department of Lymphoma and Myeloma; Division of Cancer Medicine; The University of Texas M.D. Anderson Cancer Center; Houston TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Durga","family":"Nattamai","sequence":"additional","affiliation":[{"name":"Center for Cancer Immunology Research; The University of Texas M.D. Anderson Cancer Center; Houston TX"},{"name":"Department of Lymphoma and Myeloma; Division of Cancer Medicine; The University of Texas M.D. Anderson Cancer Center; Houston TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan","family":"Harline","sequence":"additional","affiliation":[{"name":"Department of Immunology; The University of Texas M.D. Anderson Cancer Center; Houston TX"},{"name":"Center for Cancer Immunology Research; The University of Texas M.D. Anderson Cancer Center; Houston TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seung-Tae","family":"Lee","sequence":"additional","affiliation":[{"name":"Center for Cancer Immunology Research; The University of Texas M.D. Anderson Cancer Center; Houston TX"},{"name":"Department of Lymphoma and Myeloma; Division of Cancer Medicine; The University of Texas M.D. Anderson Cancer Center; Houston TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Bover","sequence":"additional","affiliation":[{"name":"Department of Immunology; The University of Texas M.D. Anderson Cancer Center; Houston TX"},{"name":"Center for Cancer Immunology Research; The University of Texas M.D. Anderson Cancer Center; Houston TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather Y.","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Biostatistics; The University of Texas M.D. Anderson Cancer Center; Houston TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veerabhadran","family":"Baladandayuthapani","sequence":"additional","affiliation":[{"name":"Department of Biostatistics; The University of Texas M.D. Anderson Cancer Center; Houston TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Delgado","sequence":"additional","affiliation":[{"name":"Center for Cancer Immunology Research; The University of Texas M.D. Anderson Cancer Center; Houston TX"},{"name":"Department of Lymphoma and Myeloma; Division of Cancer Medicine; The University of Texas M.D. Anderson Cancer Center; Houston TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amber","family":"Luong","sequence":"additional","affiliation":[{"name":"Department of Otorhinolaryngology-Head and Neck Surgery; The University of Texas Medical School at Houston; Houston TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. Eric","family":"Davis","sequence":"additional","affiliation":[{"name":"Center for Cancer Immunology Research; The University of Texas M.D. Anderson Cancer Center; Houston TX"},{"name":"Department of Lymphoma and Myeloma; Division of Cancer Medicine; The University of Texas M.D. Anderson Cancer Center; Houston TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larry W.","family":"Kwak","sequence":"additional","affiliation":[{"name":"Center for Cancer Immunology Research; The University of Texas M.D. Anderson Cancer Center; Houston TX"},{"name":"Department of Lymphoma and Myeloma; Division of Cancer Medicine; The University of Texas M.D. Anderson Cancer Center; Houston TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong-Jun","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Immunology; The University of Texas M.D. Anderson Cancer Center; Houston TX"},{"name":"Center for Cancer Immunology Research; The University of Texas M.D. Anderson Cancer Center; Houston TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sattva S.","family":"Neelapu","sequence":"additional","affiliation":[{"name":"Center for Cancer Immunology Research; The University of Texas M.D. Anderson Cancer Center; Houston TX"},{"name":"Department of Lymphoma and Myeloma; Division of Cancer Medicine; The University of Texas M.D. Anderson Cancer Center; Houston TX"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2014,5,12]]},"reference":[{"key":"10.1002\/ijc.28937-BIB0001|ijc28937-cit-0001","doi-asserted-by":"crossref","first-page":"3909","DOI":"10.1182\/blood.V89.11.3909","article-title":"The Non-Hodgkin's Lymphoma Classification Project","volume":"89","author":"A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma","year":"1997","journal-title":"Blood"},{"key":"10.1002\/ijc.28937-BIB0002|ijc28937-cit-0002","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1038\/13928","article-title":"Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma","volume":"5","author":"Bendandi","year":"1999","journal-title":"Nat Med"},{"key":"10.1002\/ijc.28937-BIB0003|ijc28937-cit-0003","doi-asserted-by":"crossref","first-page":"8309","DOI":"10.1158\/1078-0432.CCR-04-1071","article-title":"Human autologous tumor-specific T-cell responses induced by liposomal delivery of a lymphoma antigen","volume":"10","author":"Neelapu","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1002\/ijc.28937-BIB0004|ijc28937-cit-0004","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1182\/blood.V99.5.1517","article-title":"Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients","volume":"99","author":"Timmerman","year":"2002","journal-title":"Blood"},{"key":"10.1002\/ijc.28937-BIB0005|ijc28937-cit-0005","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1111\/j.1365-2141.2008.07143.x","article-title":"Developing idiotype vaccines for lymphoma: from preclinical studies to phase III clinical trials","volume":"142","author":"Park","year":"2008","journal-title":"Br J Haematol"},{"key":"10.1002\/ijc.28937-BIB0006|ijc28937-cit-0006","doi-asserted-by":"crossref","first-page":"2787","DOI":"10.1200\/JCO.2010.33.3005","article-title":"Vaccination with patient-specific tumor-derived antigen in first remission improves disease-free survival in follicular lymphoma","volume":"29","author":"Schuster","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1002\/ijc.28937-BIB0007|ijc28937-cit-0007","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1038\/nri1806","article-title":"Regulatory T cells, tumour immunity and immunotherapy","volume":"6","author":"Zou","year":"2006","journal-title":"Nat Rev Immunol"},{"key":"10.1002\/ijc.28937-BIB0008|ijc28937-cit-0008","doi-asserted-by":"crossref","first-page":"3639","DOI":"10.1182\/blood-2005-08-3376","article-title":"Intratumoral CD4+CD25+ regulatory T-cell-mediated suppression of infiltrating CD4+ T cells in B-cell non-Hodgkin lymphoma","volume":"107","author":"Yang","year":"2006","journal-title":"Blood"},{"key":"10.1002\/ijc.28937-BIB0009|ijc28937-cit-0009","doi-asserted-by":"crossref","first-page":"4051","DOI":"10.4049\/jimmunol.178.7.4051","article-title":"Follicular lymphoma intratumoral CD4+CD25+GITR+ regulatory T cells potently suppress CD3\/CD28-costimulated autologous and allogeneic CD8+CD25- and CD4+CD25- T cells","volume":"178","author":"Hilchey","year":"2007","journal-title":"J Immunol"},{"key":"10.1002\/ijc.28937-BIB0010|ijc28937-cit-0010","doi-asserted-by":"crossref","first-page":"5359","DOI":"10.1182\/blood-2007-08-105395","article-title":"Local and systemic induction of CD4+CD25+ regulatory T-cell population by non-Hodgkin lymphoma","volume":"111","author":"Mittal","year":"2008","journal-title":"Blood"},{"key":"10.1002\/ijc.28937-BIB0011|ijc28937-cit-0011","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1002\/ijc.23881","article-title":"Follicular lymphoma B cells induce the conversion of conventional CD4+ T cells to T-regulatory cells","volume":"124","author":"Ai","year":"2009","journal-title":"Int J Cancer"},{"key":"10.1002\/ijc.28937-BIB0012|ijc28937-cit-0012","doi-asserted-by":"crossref","first-page":"2957","DOI":"10.1182\/blood-2006-04-018218","article-title":"High numbers of tumor-infiltrating FOXP3-positive regulatory T cells are associated with improved overall survival in follicular lymphoma","volume":"108","author":"Carreras","year":"2006","journal-title":"Blood"},{"key":"10.1002\/ijc.28937-BIB0013|ijc28937-cit-0013","doi-asserted-by":"crossref","first-page":"5350","DOI":"10.1200\/JCO.2006.06.4766","article-title":"Immunohistochemical patterns of reactive microenvironment are associated with clinicobiologic behavior in follicular lymphoma patients","volume":"24","author":"Alvaro","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1002\/ijc.28937-BIB0014|ijc28937-cit-0014","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1182\/blood-2009-07-235598","article-title":"The architectural pattern of FOXP3-positive T cells in follicular lymphoma is an independent predictor of survival and histologic transformation","volume":"115","author":"Farinha","year":"2010","journal-title":"Blood"},{"key":"10.1002\/ijc.28937-BIB0015|ijc28937-cit-0015","doi-asserted-by":"crossref","first-page":"3431","DOI":"10.1182\/blood-2009-05-223958","article-title":"Therapeutic effect of CD137 immunomodulation in lymphoma and its enhancement by Treg depletion","volume":"114","author":"Houot","year":"2009","journal-title":"Blood"},{"key":"10.1002\/ijc.28937-BIB0016|ijc28937-cit-0016","doi-asserted-by":"crossref","first-page":"3546","DOI":"10.1182\/blood-2008-07-170274","article-title":"T-cell modulation combined with intratumoral CpG cures lymphoma in a mouse model without the need for chemotherapy","volume":"113","author":"Houot","year":"2009","journal-title":"Blood"},{"key":"10.1002\/ijc.28937-BIB0017|ijc28937-cit-0017","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1038\/ni1112","article-title":"Toll-like receptor control of the adaptive immune responses","volume":"5","author":"Iwasaki","year":"2004","journal-title":"Nat Immunol"},{"key":"10.1002\/ijc.28937-BIB0018|ijc28937-cit-0018","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/sj.onc.1210906","article-title":"Toll-like receptors and immune regulation: implications for cancer therapy","volume":"27","author":"Wang","year":"2008","journal-title":"Oncogene"},{"key":"10.1002\/ijc.28937-BIB0019|ijc28937-cit-0019","doi-asserted-by":"crossref","first-page":"8051","DOI":"10.4049\/jimmunol.175.12.8051","article-title":"Human CD4+ T cells express TLR5 and its ligand flagellin enhances the suppressive capacity and expression of FOXP3 in CD4+CD25+ T regulatory cells","volume":"175","author":"Crellin","year":"2005","journal-title":"J Immunol"},{"key":"10.1002\/ijc.28937-BIB0020|ijc28937-cit-0020","doi-asserted-by":"crossref","first-page":"4458","DOI":"10.4049\/jimmunol.0901465","article-title":"Engagement of TLR2 does not reverse the suppressor function of mouse regulatory T cells, but promotes their survival","volume":"183","author":"Chen","year":"2009","journal-title":"J Immunol"},{"key":"10.1002\/ijc.28937-BIB0021|ijc28937-cit-0021","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1111\/j.1600-065X.2009.00766.x","article-title":"The significance of OX40 and OX40L to T-cell biology and immune disease","volume":"229","author":"Croft","year":"2009","journal-title":"Immunol Rev"},{"key":"10.1002\/ijc.28937-BIB0022|ijc28937-cit-0022","doi-asserted-by":"crossref","first-page":"13138","DOI":"10.1073\/pnas.0603107103","article-title":"OX40 ligand shuts down IL-10-producing regulatory T cells","volume":"103","author":"Ito","year":"2006","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1002\/ijc.28937-BIB0023|ijc28937-cit-0023","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.4049\/jimmunol.179.3.1427","article-title":"Cutting edge: OX40 inhibits TGF-beta- and antigen-driven conversion of naive CD4 T cells into CD25+Foxp3+ T cells","volume":"179","author":"So","year":"2007","journal-title":"J Immunol"},{"key":"10.1002\/ijc.28937-BIB0024|ijc28937-cit-0024","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1084\/jem.20082205","article-title":"OX40 engagement and chemotherapy combination provides potent antitumor immunity with concomitant regulatory T cell apoptosis","volume":"206","author":"Hirschhorn-Cymerman","year":"2009","journal-title":"J Exp Med"},{"key":"10.1002\/ijc.28937-BIB0025|ijc28937-cit-0025","doi-asserted-by":"crossref","first-page":"5206","DOI":"10.1158\/0008-5472.CAN-07-6484","article-title":"OX40 agonist therapy enhances CD8 infiltration and decreases immune suppression in the tumor","volume":"68","author":"Gough","year":"2008","journal-title":"Cancer Res"},{"key":"10.1002\/ijc.28937-BIB0026|ijc28937-cit-0026","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1056\/NEJMoa041869","article-title":"Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells","volume":"351","author":"Dave","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1002\/ijc.28937-BIB0027|ijc28937-cit-0027","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1200\/JCO.1999.17.4.1244","article-title":"Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas","volume":"17","author":"Cheson","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1002\/ijc.28937-BIB0028|ijc28937-cit-0028","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S1470-2045(13)70551-5","article-title":"Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial","volume":"15","author":"Westin","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1002\/ijc.28937-BIB0029|ijc28937-cit-0029","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.jim.2007.09.006","article-title":"A novel strategy for rapid and efficient isolation of human tumor-specific CD4(+) and CD8(+) T-cell clones","volume":"331","author":"Lee","year":"2008","journal-title":"J Immunol Methods"},{"key":"10.1002\/ijc.28937-BIB0030|ijc28937-cit-0030","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/j.immuni.2009.03.019","article-title":"Functional delineation and differentiation dynamics of human CD4+ T cells expressing the FoxP3 transcription factor","volume":"30","author":"Miyara","year":"2009","journal-title":"Immunity"},{"key":"10.1002\/ijc.28937-BIB0031|ijc28937-cit-0031","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1182\/blood-2002-11-3355","article-title":"The toll-like receptor repertoire of human B lymphocytes: inducible and selective expression of TLR9 and TLR10 in normal and transformed cells","volume":"102","author":"Bourke","year":"2003","journal-title":"Blood"},{"key":"10.1002\/ijc.28937-BIB0032|ijc28937-cit-0032","doi-asserted-by":"crossref","first-page":"7558","DOI":"10.4049\/jimmunol.174.12.7558","article-title":"TLR2 agonist ameliorates established allergic airway inflammation by promoting Th1 response and not via regulatory T cells","volume":"174","author":"Patel","year":"2005","journal-title":"J Immunol"},{"key":"10.1002\/ijc.28937-BIB0033|ijc28937-cit-0033","doi-asserted-by":"crossref","first-page":"e18833","DOI":"10.1371\/journal.pone.0018833","article-title":"TLR2-dependent induction of IL-10 and Foxp3+ CD25+ CD4+ regulatory T cells prevents effective anti-tumor immunity induced by Pam2 lipopeptides in vivo","volume":"6","author":"Yamazaki","journal-title":"PLoS One"},{"key":"10.1002\/ijc.28937-BIB0034|ijc28937-cit-0034","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1084\/jem.20071341","article-title":"OX40 triggering blocks suppression by regulatory T cells and facilitates tumor rejection","volume":"205","author":"Piconese","year":"2008","journal-title":"J Exp Med"},{"key":"10.1002\/ijc.28937-BIB0035|ijc28937-cit-0035","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1007\/s00262-006-0225-8","article-title":"Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients","volume":"56","author":"Ghiringhelli","year":"2007","journal-title":"Cancer Immunol Immunother"},{"key":"10.1002\/ijc.28937-BIB0036|ijc28937-cit-0036","doi-asserted-by":"crossref","first-page":"6681","DOI":"10.4049\/jimmunol.1201363","article-title":"Cross talk between follicular Th cells and tumor cells in human follicular lymphoma promotes immune evasion in the tumor microenvironment","volume":"190","author":"Rawal","year":"2013","journal-title":"J Immunol"},{"key":"10.1002\/ijc.28937-BIB0037|ijc28937-cit-0037","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1182\/blood-2010-06-292342","article-title":"Upfront immunization with autologous recombinant idiotype Fab fragment without prior cytoreduction in indolent B-cell lymphoma","volume":"117","author":"Navarrete","year":"2011","journal-title":"Blood"},{"key":"10.1002\/ijc.28937-BIB0038|ijc28937-cit-0038","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.4049\/jimmunol.1003715","article-title":"TLR2 stimulation drives human naive and effector regulatory T cells into a Th17-like phenotype with reduced suppressive function","volume":"187","author":"Nyirenda","year":"2011","journal-title":"J Immunol"},{"key":"10.1002\/ijc.28937-BIB0039|ijc28937-cit-0039","doi-asserted-by":"crossref","first-page":"7249","DOI":"10.4049\/jimmunol.173.12.7249","article-title":"Regulatory T cell suppression and anergy are differentially regulated by proinflammatory cytokines produced by TLR-activated dendritic cells","volume":"173","author":"Kubo","year":"2004","journal-title":"J Immunol"},{"key":"10.1002\/ijc.28937-BIB0040|ijc28937-cit-0040","doi-asserted-by":"crossref","first-page":"3641","DOI":"10.4049\/jimmunol.1202752","article-title":"Antibodies targeting human OX40 expand effector T cells and block inducible and natural regulatory T cell function","volume":"191","author":"Voo","year":"2013","journal-title":"J Immunol"},{"key":"10.1002\/ijc.28937-BIB0041|ijc28937-cit-0041","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1016\/j.jaci.2006.02.014","article-title":"Toll-like receptor 2 ligands inhibit TH2 responses to mite allergen","volume":"117","author":"Taylor","year":"2006","journal-title":"J Allergy Clin Immunol"},{"key":"10.1002\/ijc.28937-BIB0042|ijc28937-cit-0042","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1007\/s00262-008-0498-1","article-title":"Protein-bound polysaccharide K augments IL-2 production from murine mesenteric lymph node CD4+ T cells by modulating T cell receptor signaling","volume":"57","author":"Asai","year":"2008","journal-title":"Cancer Immunol Immunother"},{"key":"10.1002\/ijc.28937-BIB0043|ijc28937-cit-0043","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.4049\/jimmunol.1002320","article-title":"TLR1\/TLR2 agonist induces tumor regression by reciprocal modulation of effector and regulatory T cells","volume":"186","author":"Zhang","journal-title":"J Immunol"},{"key":"10.1002\/ijc.28937-BIB0044|ijc28937-cit-0044","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1038\/ni1223","article-title":"Selected Toll-like receptor agonist combinations synergistically trigger a T helper type 1-polarizing program in dendritic cells","volume":"6","author":"Napolitani","year":"2005","journal-title":"Nat Immunol"},{"key":"10.1002\/ijc.28937-BIB0045|ijc28937-cit-0045","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1172\/JCI39293","article-title":"Using 3 TLR ligands as a combination adjuvant induces qualitative changes in T cell responses needed for antiviral protection in mice","volume":"120","author":"Zhu","year":"2010","journal-title":"J Clin Investig"},{"key":"10.1002\/ijc.28937-BIB0046|ijc28937-cit-0046","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1182\/blood-2007-03-082578","article-title":"CD70+ non-Hodgkin lymphoma B cells induce Foxp3 expression and regulatory function in intratumoral CD4+CD25 T cells","volume":"110","author":"Yang","year":"2007","journal-title":"Blood"},{"key":"10.1002\/ijc.28937-BIB0047|ijc28937-cit-0047","doi-asserted-by":"crossref","first-page":"4136","DOI":"10.1158\/1078-0432.CCR-11-0264","article-title":"T cells in tumors and blood predict outcome in follicular lymphoma treated with rituximab","volume":"17","author":"Wahlin","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1002\/ijc.28937-BIB0048|ijc28937-cit-0048","doi-asserted-by":"crossref","first-page":"3836","DOI":"10.1182\/blood-2010-07-299321","article-title":"Definition and characterization of the systemic T-cell dysregulation in untreated indolent B-cell lymphoma and very early CLL","volume":"117","author":"Christopoulos","journal-title":"Blood"},{"key":"10.1002\/ijc.28937-BIB0049|ijc28937-cit-0049","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1038\/ni.1731","article-title":"The transcription factor T-bet controls regulatory T cell homeostasis and function during type 1 inflammation","volume":"10","author":"Koch","year":"2009","journal-title":"Nat Immunol"},{"key":"10.1002\/ijc.28937-BIB0050|ijc28937-cit-0050","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1038\/nature07674","article-title":"Regulatory T-cell suppressor program co-opts transcription factor IRF4 to control T(H)2 responses","volume":"458","author":"Zheng","year":"2009","journal-title":"Nature"},{"key":"10.1002\/ijc.28937-BIB0051|ijc28937-cit-0051","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1126\/science.1172702","article-title":"CD4+ regulatory T cells control TH17 responses in a Stat3-dependent manner","volume":"326","author":"Chaudhry","year":"2009","journal-title":"Science"},{"key":"10.1002\/ijc.28937-BIB0052|ijc28937-cit-0052","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1038\/nm.2426","article-title":"Follicular regulatory T cells expressing Foxp3 and Bcl-6 suppress germinal center reactions","volume":"17","author":"Chung","year":"2011","journal-title":"Nat Med"},{"key":"10.1002\/ijc.28937-BIB0053|ijc28937-cit-0053","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1038\/leu.2011.301","article-title":"Characterization of intratumoral follicular helper T cells in follicular lymphoma: role in the survival of malignant B cells","volume":"26","author":"Ame-Thomas","year":"2012","journal-title":"Leukemia"}],"container-title":["International Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fijc.28937","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T16:44:42Z","timestamp":1625157882000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ijc.28937"}},"subtitle":["Inhibition of Regulatory T Cells in Follicular Lymphoma"],"short-title":[],"issued":{"date-parts":[[2014,5,12]]},"references-count":53,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2014,12,15]]}},"URL":"https:\/\/doi.org\/10.1002\/ijc.28937","relation":{},"ISSN":["0020-7136"],"issn-type":[{"value":"0020-7136","type":"print"}],"subject":[],"published":{"date-parts":[[2014,5,12]]}}}